Table 2.
Summary of adverse events post operation and liver function indexes at M1 in the studies.
| Studies | Treatment arms | No. | Adverse events post operation | M1 post operation (Mean (SD)) | ||||
|---|---|---|---|---|---|---|---|---|
| Pain | Fever | Nausea/vomiting | ALT (U/L) | AST (U/L) | TB (umol/L) | |||
| Liang et al. (19) | CSM-TACE | 171 | 41/171 | 31/171 | 17/171 | 37.1 (26.2) | 53.5 (35.5) | 17.4 (7.9) |
| cTACE | 164 | 29/164 | 35/164 | 12/164 | 31.0 (22.0) | 44.7 (29.2) | 15.2 (8.3) | |
| Duan et al. (20) | CSM-TACE | 38 | 21/38 | 21/38 | 8/38 | – | – | – |
| cTACE | 48 | 28/48 | 27/48 | 22/48 | – | – | – | |
| Ma et al. (16) | CSM-TACE | 94 | 34/94 | 26/94 | 10/94 | 37.8 (32.5) | 55.4 (39.8) | 17.0 (7.6) |
| cTACE | 98 | 22/98 | 14/98 | 11/98 | 35.0 (22.2) | 47.0 (27.2) | 14.5 (9.2) | |
| Zhao et al. (21) | CSM-TACE | 42 | 24/42 | 16/42 | 5/42 | 47.0 (27.8) | 62.0 (49.1) | 19.0 (11.1) |
| cTACE | 47 | 15/47 | 7/47 | 2/47 | 31.0 (19.9) | 49.5 (37.1) | 18.0 (10.2) | |
| Liu et al. (22) | CSM-TACE | 14 | 0/14 | 0/14 | – | – | – | – |
| cTACE | 9 | 2/9 | 1/9 | – | – | – | – | |
| Xiao et al. (23) | CSM-TACE | 26 | 22/26 | 16/26 | 3/26 | – | – | – |
| cTACE | 32 | 28/32 | 27/32 | 5/32 | – | – | – | |
| Liu et al. (24) | CSM-TACE | 31 | 6/31 | 10/31 | 23/31 | – | – | – |
| cTACE | 40 | 8/40 | 23/40 | 37/40 | – | – | – | |
| Li et al. (25) | CSM-TACE | 34 | 8/34 | – | – | – | – | – |
| cTACE | 33 | 9/33 | – | – | – | – | – | |
| Wang et al. (26) | CSM-TACE | 45 | 6/45 | 4/45 | 13/45 | 42.6 (10.7) | 48.6 (10.8) | – |
| cTACE | 45 | 4/45 | 5/45 | 12/45 | 56.6 (10.8) | 59.5 (9.1) | – | |
| Zhou et al. (27) | CSM-TACE | 34 | 11/34 | – | – | 38.8 (19.0) | 45.4 (15.3) | 16.7 (4.2) |
| cTACE | 30 | 20/30 | – | – | 56.8 (30.8) | 60.8 (32.3) | 20.9 (8.5) | |
| Xu et al. (28) | CSM-TACE | 32 | 17/32 | 10/32 | 8/32 | 52.3 (4.9) | 59.8 (6.2) | 24.6 (2.0) |
| cTACE | 26 | 21/26 | 12/26 | 8/26 | 57.7 (4.9) | 63.3 (6.3) | 26.8 (2.2) | |
| Lin et al. (29) | CSM-TACE | 33 | 5/33 | 3/33 | 7/33 | – | – | – |
| cTACE | 32 | 8/32 | 4/32 | 10/32 | – | – | – | |
| Xiang et al. (14) | CSM-TACE | 36 | 8/36 | 5/36 | 2/36 | 41.2 (24.5) | 50.4 (25.3) | 17.0 (5.7) |
| cTACE | 37 | 6/37 | 3/37 | 2/37 | 38.1 (21.1) | 45.3 (24.2) | 15.1 (9.6) | |
| Wu et al. (30) | CSM-TACE | 24 | 15/24 | – | – | 40.5 (22.2) | 45.7 (15.5) | 16.9 (4.2) |
| cTACE | 30 | 26/30 | – | – | 56.8 (30.8) | 60.8 (32.3) | 20.9 (8.5) | |
| Ou et al. (31) | CSM-TACE | 46 | – | – | – | – | – | – |
| cTACE | 41 | – | – | – | – | – | – | |
| Chen et al. (15) | CSM-TACE | 22 | 8/22 | 8/22 | 6/22 | – | – | – |
| cTACE | 20 | 11/20 | 9/20 | 9/20 | – | – | – | |
SD, standard deviation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TB, total bilirubin; CSM-TACE, CalliSpheres® microspheres transarterial chemoembolization; cTACE, conventional transarterial chemoembolization. “-” indicated the missing data.